Glimepiride

Glimepiride

SCHEMBL16084

CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCC(C)CC3)cc2)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC8KCNJ11

The experimentally established mechanism targets of Glimepiride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC8 known ✓ Q09428 2/20 0.43
KCNJ11 known ✓ Q14654 1/20 0.43
CYP2C9 P11712 4/20 1.00
ABCC3 O15438 3/20 1.00
ABCC4 O15439 3/20 1.00
ABCB11 O95342 3/20 1.00
HIF1A Q16665 3/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
TBXA2R P21731 2/20 1.00
NR1I3 Q14994 2/20 1.00
AKR1C3 P42330 1/20 1.00
AKR1C1 Q04828 1/20 1.00
KCNH2 Q12809 2/20 0.68
PPARG P37231 8/20 0.57
LMNA P02545 4/20 0.47
CYP3A4 P08684 3/20 0.47
TSHR P16473 3/20 0.47
BLM P54132 3/20 0.47
MAPT P10636 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glimepiride SCHEMBL16086 1.00 CYP2C9 (1.00) CYP2C9ABCC3ABCC4ABCB11HIF1A
Glimepiride SCHEMBL1331215 1.00 CYP2C9 (1.00) CYP2C9ABCC3ABCC4ABCB11HIF1A
Glimepiride SCHEMBL14965363 1.00 CYP2C9 (1.00) CYP2C9ABCC3ABCC4ABCB11HIF1A
Glimepiride SCHEMBL5081711 0.99 CYP2C9 (0.98) CYP2C9ABCC3ABCC4ABCB11HIF1A
Glimepiride SCHEMBL20877218 0.99 CYP2C9 (0.98) CYP2C9ABCC3ABCC4ABCB11HIF1A
Glimepiride SCHEMBL6381985 0.98 CYP2C9 (0.95) CYP2C9ABCC3ABCC4ABCB11HIF1A
SCHEMBL11185683 0.93 CYP2C9 (0.86) CYP2C9ABCC3ABCC4ABCB11HIF1A
Glimepiride SCHEMBL23782324 0.93 CYP2C9 (0.85) CYP2C9ABCC3ABCC4ABCB11HIF1A
Glimepiride SCHEMBL28086181 0.93 CYP2C9 (0.85) CYP2C9ABCC3ABCC4ABCB11HIF1A
SCHEMBL11189249 0.92 CYP2C9 (0.86) CYP2C9ABCC3ABCC4ABCB11HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 37029 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122005498-A Engineering exosome drug delivery system with enhanced membrane fluidity and preparation method and application thereof 四川大学 2026-05-12 CN claimed
US-20260124282-A1 DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) 2026-05-07 US claimed
EP-4734978-A2 COMBINATION THERAPIES USING PSILOCYBIN University of Padova (IT) 2026-05-06 EP claimed
US-20260115210-A1 METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS REMEDY PHARMACEUTICALS, INC. (US) 2026-04-30 US claimed
US-12611416-B2 Methods of treating ischemic stroke at risk for cerebral or cerebellar edema REMEDY PHARMACEUTICALS, INC. (US) 2026-04-28 US claimed
EP-4717267-A1 SYNERGISTIC COMBINATION FOR TREATING CANCER FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) 2026-04-01 EP claimed
US-20260069550-A1 TRANSDERMAL DELIVERY OF ANTIDIABETIC AGENTS RITTENHOUSE CHRISTINE (US) 2026-03-12 US claimed
EP-4705280-A1 DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE Purdue Research Foundation (US) 2026-03-11 EP claimed
EP-4704933-A1 DEVICES AND METHODS FOR PREPARING AND CONDITIONING BIOLOGICAL ASSEMBLIES FOR MINIMALLY INVASIVE DELIVERY FOR TISSUE ENGINEERING, CELL THERAPIES AND OTHER THERAPEUTIC APPLICATIONS Volumina Medical SA (CH) 2026-03-11 EP claimed
EP-4691496-A1 PHARMACEUTICAL PREPARATION CONTAINING GLP-1 FUSION PROTEIN AND USE THEREOF Guangzhou Innogen Pharmaceutical Group Co., Ltd. (CN) 2026-02-11 EP claimed
WO-1999003478-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOCIDASE INHIBITOR SMITHKLINE BEECHAM P.L.C. (GB) 1999-01-28 WO claimed
WO-1999003477-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND DIGUANIDE SMITHKLINE BEECHAM P.L.C. (GB) 1999-01-28 WO claimed
WO-1998057649-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND SULPHONYLUREA SMITHKLINE BEECHAM PLC (GB) 1998-12-23 WO claimed
WO-1998011884-A1 USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES KNOLL AKTIENGESELLSCHAFT (DE) 1998-03-26 WO claimed
CN-1104888-A Pharmaceutical composition for preventing or treating arteriosclerosis HOECHST JAPAN (JP) 1995-07-12 CN claimed
US-5416105-A Cardiovascular orders using 1-(4-(2-(3-ethyl-4-methyl-2-oxo-3-pyroline-1 -carboxyamido)ethyl)phenylsulfonyl)-3-(4-methyl cyclohexyl)urea HOECHST JAPAN LIMITED (JP) 1995-05-16 US claimed
EP-0604853-A2 Pharmaceutical composition for preventing or treating arteriosclerosis HOECHST JAPAN LIMITED (JP) 1994-07-06 EP claimed
EP-0601001-A1 PHARMACEUTICAL COMPOSITION CONTAINING 3-GUANIDINOPROPIONIC ACID AND PIOGLITAZONE GLIBENCLAMIDE OR GLIMEPIRIDE. UPJOHN CO (US) 1994-06-15 EP claimed
WO-1993003724-A1 PHARMACEUTICAL COMPOSITION CONTAINING 3-GUANIDINOPROPIONIC ACID AND PIOGLITAZONE GLIBENCLAMIDE OR GLIMEPIRIDE THE UPJOHN COMPANY (US) 1993-03-04 WO claimed
US-4379785-A Heterocyclic substituted sulfonyl ureas, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1983-04-12 US claimed